U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 18 results

Status:
US Approved Rx (2021)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prog...
Status:
US Approved Rx (2024)
First approved in 2004

Class (Stereo):
CHEMICAL (EPIMERIC)



Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) ...
Status:
US Approved Rx (2009)
First approved in 2002

Class (Stereo):
CHEMICAL (ABSOLUTE)



Treprostinil (marketed under the trade names Remodulin for infusion) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in ...
Status:
US Approved Rx (2008)
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)



Epoprostenol (marketed as FLOLAN, VELETRI) is a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. Epoprostenol (PGI2, PGX, prostacyclin), a metabolite of arachidonic acid, is a naturally occurring prostaglandin with pote...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Pimilprost (SM-10902) and its free acid, SM-10906 are new stable 3-oxa-methano prostaglandin (PG) I1 analogs, SM-10902 is a prodrug of SM-10906. SM-10906, but not SM-10902 was demonstrated to be an agonist for IP receptors. SM-10906 was shown to exer...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Cicaprost is a prostacyclin receptor (IP) agonist and orally active prostacyclin analog with potent systemic and pulmonary vasodilatation and anti-inflammatory activity. In preclinical models, Cicaprost treatment largely prevented the hypercholestero...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Ciprostene is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene wa...
15-Epi-prostaglandin E2 (15R-Prostaglandin E2) is the C-15 epimer of the naturally occurring 15S-Prostaglandin E2 (15S-PGE2) isomer. 15-Epi-prostaglandin E2 is the most physiologically abundant eicosanoid, which is produced predominantly from arachid...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (EPIMERIC)



Beraprost is a stable, orally active prostacyclin analogue. Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca2+ from intracellular storage sites. This reduction in the influx of Ca2+ has been postula...
Status:
US Approved Rx (2024)
First approved in 2004

Class (Stereo):
CHEMICAL (EPIMERIC)



Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) ...

Showing 1 - 10 of 18 results